Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
CING Stock Chart & Stats
$6.27
-$0.31(-6.60%)
At close: 4:00 PM EST
$6.27
-$0.31(-6.60%)
Day’s Range― - ―
52-Week Range$3.20 - $7.92
Previous CloseN/A
Volume136.88K
Average Volume (3M)190.99K
Market Cap
$48.52M
Enterprise Value$33.61M
Total Cash (Recent Filing)$6.12M
Total Debt (Recent Filing)$4.58M
Price to Earnings (P/E)―
Beta5.98
Next Earnings
Mar 06, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding7,738,730
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-58.01
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$37.00Price Target Upside490.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$2.39M
Bulls Say, Bears Say
Bulls Say
Commercial StrategyPartnership with Indegene combined with the hiring of an experienced Chief Commercial Officer strengthens commercialization capabilities and launch readiness for CTx-1301.
Product DifferentiationPrecision Timed Release (PTR) technology enabling once-daily dosing with all-day efficacy and potential best-in-class onset and duration differentiates CTx-1301 in the ADHD market.
Regulatory ApprovalFDA acceptance of the NDA for CTx-1301 and a potential mid-2026 approval opens a clear pathway to commercialization and the start of product revenues.
Bears Say
Financial PerformanceA reported Q3 net loss of $7.3 million and EPS of $(1.35) highlights ongoing operating losses and the potential need for additional funding before profitability.
Guidance UncertaintyManagement's lack of forward guidance increases uncertainty around revenue trajectory and cash runway, reducing investor visibility ahead of commercialization.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.20 and its highest was $7.92 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $48.52M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Mar 06, 2026 which is in 5 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Nov 13, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.47.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.63.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 7,738,730 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -12.368%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (490.11% Upside)
$37.00 (490.11% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $166.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
-284.50%
Trailing 12-Months
Asset Growth
162.70%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$37.00
▲(490.11% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
1.78% Insiders
0.96% Mutual Funds
1.02% Other Institutional Investors
94.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---